Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  American journal of clinical and experimental urology

• Publication date

  2014-10-02

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 25374925PMCID PMC4219316
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells

  2014cited by this paper
• JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells.

  2013cited by this paper
• Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.

  2013cited by this paper
• Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

  2012cited by this paper
• IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR

  2011cited by this paper
• The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

  2011cited by this paper
• Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

  2010cited by this paper
• Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

  2010cited by this paper
• Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2

  2009cited by this paper
• Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells

  2009cited by this paper
• Tumorigenesis and Neoplastic Progression Suppressor of Cytokine Signaling (SOCS)-1 Is Expressed in Human Prostate Cancer and Exerts Growth-Inhibitory Function through Down-Regulation of Cyclins and Cyclin-Dependent Kinases

  2009cited by this paper
• Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.

  2009influential reference
• Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling.

  2009cited by this paper
• Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

  2008cited by this paper
• Interleukin‐6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression

  2007cited by this paper
• Inflammation in prostate carcinogenesis

  2007cited by this paper
• Androgen deprivation increases p300 expression in prostate cancer cells.

  2007cited by this paper
• Interleukin‐6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival

  2007cited by this paper
• The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1

  2007cited by this paper
• Regulation of growth of prostate cancer cells selected in the presence of interleukin‐6 by the anti‐interleukin‐6 antibody CNTO 328

  2006cited by this paper
• Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D.

  2006cited by this paper
• Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer.

  2006cited by this paper
• Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.

  2006cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.

  2005cited by this paper
• A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells

  2005cited by this paper
• Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells

  2004cited by this paper
• CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice

  2004cited by this paper
• An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.

  2004cited by this paper
• The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancer

  2004cited by this paper
• Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways

  2003cited by this paper
• Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.

  2003cited by this paper
• Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.

  2003cited by this paper
• p300 in prostate cancer proliferation and progression.

  2003cited by this paper
• Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.

  2003cited by this paper
• Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.

  2002cited by this paper
• Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.

  2002cited by this paper
• Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.

  2002cited by this paper
• p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6.

  2002influential reference
• Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways*

  2002cited by this paper
• Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells*

  2002cited by this paper
• Interleukin-6 is an autocrine growth factor in human prostate cancer.

  2001cited by this paper
• Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells

  2001cited by this paper
• Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice

  2001cited by this paper
• Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression.

  2001cited by this paper
• Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.

  2001influential reference
• Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.

  2000cited by this paper
• Short Communication Increased Expression of the Interleukin-11 Receptor and Evidence of STAT3 Activation in Prostate Carcinoma

  2000cited by this paper
• STAT3 mediates IL‐6‐induced neuroendocrine differentiation in prostate cancer cells

  2000cited by this paper
• Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue

  2000cited by this paper
• Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells.

  2000cited by this paper
• Serum interleukin 6 as a prognostic factor in patients with prostate cancer.

  2000cited by this paper
• Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines.

  2000cited by this paper
• Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells.

  1999cited by this paper
• Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

  1998cited by this paper
• Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.

  1998cited by this paper
• Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.

  1997cited by this paper
• Stromal cells from human benign prostate hyperplasia produce a growth‐inhibitory factor for LNCaP prostate cancer cells, identified as interleukin‐6

  1996cited by this paper
• P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo.

  1996cited by this paper
• Interleukin-6: a candidate mediator of human prostate cancer morbidity.

  1995influential reference
• Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.

  1995cited by this paper
• Letter: Cancer xenografts in nude mice.

  1976cited by this paper

• Anticancer (cytotoxic, anticlonogenic, antimetastatic, immunomodulatory actions) properties of 3,5‐dibromosalicylaldehyde against glioblastoma cells and DFT analyses (FT‐IR, Raman, NMR, UV) as well as a molecular docking study

  2025cites this paper
• Differential Expression of Key Oncogenic and Tumor Suppressor MicroRNAs Induced by Andrographolide in Androgen-Independent PC3 and Androgen-Dependent LNCaP Prostate Cancer Cells

  2025cites this paper
• The heat of the battle: inflammation’s role in prostate cancer development and inflammation-targeted therapies

  2025cites this paper
• Perinatal exposure to BPA leads to pronounced prostatic morphophysiological disorders in a rodent model of induced hyperplasia.

  2025cites this paper
• Fabiana imbricata Ruiz & Pav. (Solanaceae) essential oil analysis in prostate cancer cells: relevance of reactive oxygen species in proapoptotic activity.

  2025cites this paper
• Serum cytokine profiling identifies IL-17A and IL-10 as prognostic biomarkers for disease outcome in pediatric acute lymphoblastic leukemia.

  2025cites this paper
• Caffeic acid hinders the proliferation and migration through inhibition of IL-6 mediated JAK-STAT-3 signaling axis in human prostate cancer

  2024cites this paper
• Cancer stem cell in prostate cancer progression, metastasis and therapy resistance.

  2023cites this paper
• Chemopreventive Activity of Ellagitannins from Acer pseudosieboldianum (Pax) Komarov Leaves on Prostate Cancer Cells

  2023cites this paper
• Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators

  2023cites this paper
• Inflammation in Urological Malignancies: The Silent Killer

  2023cites this paper
• Melatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application

  2023cites this paper
• Inflammatory responses during trichomoniasis: The role of Toll‐like receptors and inflammasomes

  2023cites this paper
• Apoptosis induction of essential oils from Artemisia arborescens L. in human prostate cancer cells.

  2022cites this paper
• Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes.

  2022cites this paper
• World Trade Center Dust Exposure Promotes Cancer in PTEN-deficient Mouse Prostates

  2022cites this paper
• The Correlation Between Platelet Count and Survival in Prostate Cancer

  2022cites this paper
• Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue

  2022cites this paper
• Ciliary Neurotrophic Factor Modulates Multiple Downstream Signaling Pathways in Prostate Cancer Inhibiting Cell Invasiveness

  2022cites this paper
• Anticancer activity and metabolic alteration in colon and prostate cancer cells by novel moxifloxacin conjugates with fatty acids.

  2022cites this paper
• The Real Cytotoxic Effect of Artemisinins on Colon Cancer Cells in a Physiological Cell Culture Setting. How Composition of the Culture Medium Biases Experimental Findings

  2021cites this paper
• Protective effect of the association of curcumin with piperine on prostatic lesions: New perspectives on BPA-induced carcinogenesis.

  2021cites this paper
• Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer

  2021cites this paper
• Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer

  2021cites this paper
• Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery

  2021cites this paper
• Pathology and Molecular Mechanisms of Perineural Spread of Tumors

  2021cites this paper
• Evaluation of the anticancer activity of singly and doubly modified analogues of C20-epi-salinomycin.

  2021cites this paper
• Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?

  2021cites this paper
• Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms

  2020cites this paper
• Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis

  2020cites this paper
• Computer-aided prediction and design of IL-6 inducing peptides: IL-6 plays a crucial role in COVID-19

  2020cites this paper
• Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance

  2020cites this paper
• Evaluation of cytokine expression and circulating immune cell subsets as potential parameters of acute radiation toxicity in prostate cancer patients

  2020cites this paper
• An organotin indomethacin derivative inhibits cancer cell proliferation and synergizes the antiproliferative effects of lapatinib in breast cancer cells.

  2020cites this paper
• Antiproliferative and Anti-invasion Effects of Carvacrol on PC3 Human Prostate Cancer Cells through Reducing pSTAT3, pAKT, and pERK1/2 Signaling Proteins

  2019cites this paper
• Migration and Invasion Enhancer 1 Is an NF-ĸB-Inducing Gene Enhancing the Cell Proliferation and Invasion Ability of Human Prostate Carcinoma Cells In Vitro and In Vivo

  2019cites this paper
• Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46

  2019cites this paper
• Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine.

  2019cites this paper
• Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth

  2019cites this paper
• Chlamydia trachomatis Growth and Cytokine mRNA Response in a Prostate Cancer Cell Line

  2019cites this paper
• GCN5 inhibition prevents IL-6-induced prostate cancer metastases through PI3K/PTEN/Akt signaling by inactivating Egr-1

  2018cites this paper
• Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1

  2018influential citation
• Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer

  2018cites this paper
• The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells

  2018cites this paper
• Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.

  2018cites this paper
• Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats

  2018cites this paper
• AIRE promotes androgen-independent prostate cancer by directly regulating IL-6 and modulating tumor microenvironment

  2018cites this paper
• The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

  2018cites this paper
• Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer

  2018cites this paper
• Lipid pathway deregulation in advanced prostate cancer

  2018cites this paper
• A role for paracrine interleukin‐6 signaling in the tumor microenvironment in prostate tumor growth

  2018influential citation
• Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis

  2018cites this paper
• Molecular Mechanisms of Advanced Prostate Cancer

  2018influential citation
• Study on expression of IL-6/JAK/STAT3 signaling pathway in category IIIB prostatitis

  2018cites this paper
• Effects of Thymoquinone on IL-6 Gene Expression and Some Cellular Signaling Pathways in Prostate Cancer PC3 Cells

  2017influential citation
• Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer

  2017cites this paper
• Biological Effects of Hesperetin on Interleukin-6/Phosphorylated Signal Transducer and Activator of Transcription 3 Pathway Signaling in Prostate Cancer PC3 Cells

  2017influential citation
• The mysterious relation between inflammation and prostate cancer

  2017cites this paper
• Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway

  2017cites this paper
• Racial disparities in prostate cancer: a molecular perspective.

  2017cites this paper
• Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue

  2017cites this paper
• Gallic Acid Inhibits Invasion and Reduces IL-6 Gene Expression, pSTAT3, pERK1/2, and pAKT Cellular Signaling Proteins in Human Prostate Cancer DU-145 Cells

  2017cites this paper
• Avaliação dos efeitos da imersão diária em água termomineral de Caldas da Imperatriz-SC na inflamação periférica em camundongos

  2016cites this paper
• Cancer Stem Cells: Metastasis and Evasion From the Host Immune Responses

  2016cites this paper
• SOCS 3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells

  2016cites this paper
• The reduction of IL-6 gene expression, pAKT, pERK1/2, pSTAT3 signaling pathways and invasion activity by gallic acid in prostate cancer PC3 cells.

  2016cites this paper
• Elevated IL-6 levels correlate with the development of intervertebral disc degeneration : a case-control study and meta-analysis

  2016cites this paper
• MiR-218 impedes IL-6-induced prostate cancer cell proliferation and invasion via suppression of LGR4 expression.

  2016cites this paper
• SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells

  2016cites this paper
• SOCIOECONOMIC AND BEHAVIORAL FACTORS CONTRIBUTING TO RACIAL DISPARITIES IN PROSTATE CANCER

  2016cites this paper
• Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review

  2016cites this paper
• Evaluating the effects of ellagic acid on pSTAT3, pAKT, and pERK1/2 signaling pathways in prostate cancer PC3 cells.

  2016cites this paper
• Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro

  2016cites this paper
• The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment

  2016cites this paper
• c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer

  2016cites this paper
• Avian leukosis virus subgroup J induces VEGF expression via NF-κB/PI3K-dependent IL-6 production

  2016cites this paper
• Chronic inflammatory mediators enhance prostate cancer development and progression.

  2015cites this paper
• Macrófagos asociados a tumores contribuyen a la progresión del cáncer de próstata

  2015cites this paper
• Synthesis and evaluation of naphthalene-based thiosemicarbazone derivatives as new anticancer agents against LNCaP prostate cancer cells

  2015cites this paper
• Linking obesogenic dysregulation to prostate cancer progression

  2015cites this paper
• NFATc1 Promotes Prostate Tumorigenesis and Overcomes PTEN Loss-Induced Senescence

  2015cites this paper
• A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer.

  2015cites this paper